DOYUN PARK M.D.
Prescription History 1982984258
Internal Medicine - Hematology in Springfield, MA
Medicare Part D Prescription History
Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for DOYUN PARK M.D., an active Hematology specialist practicing in Springfield, MA. Our medical registry currently tracks 10 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 390 documented patient claims. Among these therapy options, the most frequently utilized medication is Eliquis, which accounts for 200 claims alone. Use the table below to sort by claims, cost, or utilization compared with the state average; select any medication for its full profile.
| Medication | Prescriptions (2023)Rx (2023) | Avg Cost per FillCost / Fill | Vs. Other MA PrescribersVs. MA Avg |
|---|---|---|---|
| EliquisApixaban | 200 | $650.38▼ below MA avg | ▲ More than typical |
About Eliquis: Apixaban is used to prevent serious blood clots from forming due to a certain irregular heartbeat (atrial fibrillation) or after hip/knee replacement surgery. Show more ▾ With atrial fibrillation, part of the heart does not beat the way it should. This can lead to blood clots forming, which can travel to other parts of your body (such as the lungs or legs) or increase your risk for stroke. In the United States, apixaban is also approved to treat certain types of blood clots (deep vein thrombosis-DVT, pulmonary embolus-PE) and to prevent them from forming again. Apixaban is an anticoagulant that works by blocking certain clotting proteins in your blood. In 2023, this provider wrote 200 Medicare prescriptions for Eliquis, about 2.6 times the volume of the typical Massachusetts prescriber of this medication (77). Medicare paid an average of $650.38 per fill, versus $792.72 statewide. How often this provider prescribes it This provider prescribes this medication more often than the average MA prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill This provider's average cost per fill is below the MA average for this medication. 225 30-Day Fills standardized to 30-day supplies 6,660 Days of Medication total across all patients in 2023 | |||
| Hydroxyurea | 50 | $28.49▼ below MA avg | ▲ More than typical |
About Hydroxyurea: This medication is used by people with sickle cell anemia to reduce the number of painful crises caused by the disease and to reduce the need for blood transfusions. Show more ▾ Some brands are also used to treat certain types of cancer (such as chronic myelogenous leukemia, squamous cell carcinomas). An antineoplastic agent that inhibits DNA synthesis through the inhibition of ribonucleoside diphosphate reductase. In 2023, this provider wrote 50 Medicare prescriptions for Hydroxyurea, about 1.6 times the volume of the typical Massachusetts prescriber of this medication (31). Medicare paid an average of $28.49 per fill, versus $35.78 statewide. How often this provider prescribes it This provider prescribes this medication more often than the average MA prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill This provider's average cost per fill is below the MA average for this medication. 77.1 30-Day Fills standardized to 30-day supplies 2,239 Days of Medication total across all patients in 2023 | |||
| XareltoRivaroxaban | 35 | $661.35▼ below MA avg | ≈ Typical |
About Xarelto: Rivaroxaban is used to prevent blood clots from forming due to a certain irregular heartbeat (atrial fibrillation) or after hip or knee replacement surgery. Show more ▾ It is also used to prevent blood clots from forming in high-risk patients with limited mobility during their hospital stay and after discharge. In addition, rivaroxaban is used to treat blood clots (such as in deep vein thrombosis-DVT or pulmonary embolus-PE) and to prevent the blood clots from forming again. Rivaroxaban may be used in children to prevent blood clots from forming after a certain heart surgery (Fontan procedure). Rivaroxaban is an anticoagulant that works by blocking certain clotting proteins in your blood. A morpholine and thiophene derivative that functions as a FACTOR XA INHIBITOR and is used in the treatment and prevention of DEEP-VEIN THROMBOSIS and PULMONARY EMBOLISM. It is also used for the prevention of STROKE and systemic embolization in patients with non-valvular ATRIAL FIBRILLATION, and for the prevention of atherothrombotic events in patients after an ACUTE CORONARY SYNDROME. In 2023, this provider wrote 35 Medicare prescriptions for Xarelto, about 88% of the volume of the typical Massachusetts prescriber of this medication (40). Medicare paid an average of $661.35 per fill, versus $930.26 statewide. How often this provider prescribes it This provider's prescribing volume for this medication is in line with the average MA prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill This provider's average cost per fill is below the MA average for this medication. 42 30-Day Fills standardized to 30-day supplies 1,242 Days of Medication total across all patients in 2023 | |||
| Lenalidomide | 18 | $15,016.39 | ≈ Typical |
About Lenalidomide: Lenalidomide is used to treat various types of cancers. Show more ▾ It works by slowing or stopping the growth of cancer cells. It is also used to treat anemia in patients with certain blood/bone marrow disorders (myelodysplastic syndromes-MDS). Lenalidomide may lessen the need for blood transfusions. Lenalidomide is not recommended for the treatment of a certain type of cancer (chronic lymphocytic leukemia) because of the increased risk of serious heart-related side effects and death. If you have this type of cancer, talk to your doctor about the risks of using this medication. A phthalimide and piperidone derivative that has immunomodulatory and antiangiogenic properties. It is used for the treatment of transfusion-dependent anemia in MYELODYSPLASTIC SYNDROMES, and for the treatment of MULTIPLE MYELOMA, and relapsed or refractory MANTLE CELL LYMPHOMA. In 2023, this provider wrote 18 Medicare prescriptions for Lenalidomide, about the same volume as the typical Massachusetts prescriber of this medication (18). Medicare paid an average of $15,016.39 per fill, versus $14,491.57 statewide. How often this provider prescribes it This provider's prescribing volume for this medication is in line with the average MA prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill Gross Part D cost per fill; not the patient's out-of-pocket price. 18 30-Day Fills standardized to 30-day supplies 504 Days of Medication total across all patients in 2023 | |||
| RevlimidLenalidomide | 17 | $17,928.43 | ▼ Less than typical |
About Revlimid: Lenalidomide is used to treat various types of cancers. Show more ▾ It works by slowing or stopping the growth of cancer cells. It is also used to treat anemia in patients with certain blood/bone marrow disorders (myelodysplastic syndromes-MDS). Lenalidomide may lessen the need for blood transfusions. Lenalidomide is not recommended for the treatment of a certain type of cancer (chronic lymphocytic leukemia) because of the increased risk of serious heart-related side effects and death. If you have this type of cancer, talk to your doctor about the risks of using this medication. A phthalimide and piperidone derivative that has immunomodulatory and antiangiogenic properties. It is used for the treatment of transfusion-dependent anemia in MYELODYSPLASTIC SYNDROMES, and for the treatment of MULTIPLE MYELOMA, and relapsed or refractory MANTLE CELL LYMPHOMA. In 2023, this provider wrote 17 Medicare prescriptions for Revlimid, about a third of the volume of the typical Massachusetts prescriber of this medication (47). Medicare paid an average of $17,928.43 per fill, versus $17,885.48 statewide. How often this provider prescribes it This provider prescribes this medication less often than the average MA prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill Gross Part D cost per fill; not the patient's out-of-pocket price. 17 30-Day Fills standardized to 30-day supplies 462 Days of Medication total across all patients in 2023 | |||
| Imatinib Mesylate | 16 | $660.41▼ below MA avg | ▼ Less than typical |
About Imatinib Mesylate: This medication is used to treat certain types of cancer (such as acute lymphoblastic leukemia, chronic myeloid leukemia, gastrointestinal stromal tumors, and myelodysplastic/myeloproliferative diseases). Show more ▾ It works by slowing or stopping the growth of cancer cells. Imatinib may also be used to treat certain immune system disorders (such as aggressive systemic mastocytosis, hypereosinophilic syndrome). A tyrosine kinase inhibitor and ANTINEOPLASTIC AGENT that inhibits the BCR-ABL kinase created by chromosome rearrangements in CHRONIC MYELOID LEUKEMIA and ACUTE LYMPHOBLASTIC LEUKEMIA, as well as PDG-derived tyrosine kinases that are overexpressed in gastrointestinal stromal tumors. In 2023, this provider wrote 16 Medicare prescriptions for Imatinib Mesylate, about 67% of the volume of the typical Massachusetts prescriber of this medication (24). Medicare paid an average of $660.41 per fill, versus $3,091.39 statewide. How often this provider prescribes it This provider prescribes this medication less often than the average MA prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill This provider's average cost per fill is below the MA average for this medication. 16 30-Day Fills standardized to 30-day supplies 480 Days of Medication total across all patients in 2023 | |||
| Gabapentin | 15 | $9.90▼ below MA avg | ▼ Less than typical |
About Gabapentin: Gabapentin is used with other medications to prevent and control seizures. Show more ▾ It is also used to relieve nerve pain following shingles (a painful rash due to herpes zoster infection) in adults. Gabapentin is known as an anticonvulsant or antiepileptic drug. A cyclohexane-gamma-aminobutyric acid derivative that is used for the treatment of PARTIAL SEIZURES; NEURALGIA; and RESTLESS LEGS SYNDROME. In 2023, this provider wrote 15 Medicare prescriptions for Gabapentin, about 19% of the volume of the typical Massachusetts prescriber of this medication (79). Medicare paid an average of $9.90 per fill, versus $20.16 statewide. How often this provider prescribes it This provider prescribes this medication less often than the average MA prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill This provider's average cost per fill is below the MA average for this medication. 15 30-Day Fills standardized to 30-day supplies 393 Days of Medication total across all patients in 2023 | |||
| PomalystPomalidomide | 15 | $21,851.58 | ▼ Less than typical |
About Pomalyst: Pomalidomide is used to treat certain types of cancers (such as multiple myeloma, Kaposi sarcoma). Show more ▾ It works by slowing or stopping the growth of cancer cells. In 2023, this provider wrote 15 Medicare prescriptions for Pomalyst, about half the volume of the typical Massachusetts prescriber of this medication (28). Medicare paid an average of $21,851.58 per fill, versus $20,426.54 statewide. How often this provider prescribes it This provider prescribes this medication less often than the average MA prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill Gross Part D cost per fill; not the patient's out-of-pocket price. 15 30-Day Fills standardized to 30-day supplies 420 Days of Medication total across all patients in 2023 | |||
| ImbruvicaIbrutinib | 12 | $16,274.59 | ▼ Less than typical |
About Imbruvica: This medication is used to treat certain cancers (such as mantle cell or marginal zone lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma, Waldenstrom's macroglobulinemia). Show more ▾ Ibrutinib belongs to a class of drugs known as kinase inhibitors. It works by slowing or stopping the growth of cancer cells. Ibrutinib is also used to treat a certain problem that may occur after a stem cell transplant (chronic graft versus host disease). It works by weakening your body's defense system (immune system). In 2023, this provider wrote 12 Medicare prescriptions for Imbruvica, about a third of the volume of the typical Massachusetts prescriber of this medication (30). Medicare paid an average of $16,274.59 per fill, versus $14,871.47 statewide. How often this provider prescribes it This provider prescribes this medication less often than the average MA prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill Gross Part D cost per fill; not the patient's out-of-pocket price. 12 30-Day Fills standardized to 30-day supplies 350 Days of Medication total across all patients in 2023 | |||
| NinlaroIxazomib Citrate | 12 | $12,485.66▼ below MA avg | ▼ Less than typical |
About Ninlaro: This medication is used to treat a certain type of cancer (multiple myeloma). Show more ▾ It works by slowing or stopping the growth of cancer cells. In 2023, this provider wrote 12 Medicare prescriptions for Ninlaro, about half the volume of the typical Massachusetts prescriber of this medication (23). Medicare paid an average of $12,485.66 per fill, versus $12,568.94 statewide. How often this provider prescribes it This provider prescribes this medication less often than the average MA prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill This provider's average cost per fill is below the MA average for this medication. 12 30-Day Fills standardized to 30-day supplies 336 Days of Medication total across all patients in 2023 | |||
About this data. The prescription history for DOYUN PARK M.D. is compiled from the Centers for Medicare & Medicaid Services (CMS) Medicare Part D Prescriber Public Use File for calendar year 2023, the most recent federal release. Figures cover prescriptions filled for Medicare Part D beneficiaries only; prescriptions under private insurance, Medicaid, or self-pay plans are not included. Because prescribing decisions are generally consistent across coverage types, this record offers a useful view of the overall Hematology prescribing approach at this Springfield, MA practice.
Reading the costs. Drug costs are gross amounts paid to pharmacies under Part D, including both plan and beneficiary payments. They are not the price a patient pays at the pharmacy counter. Medications with fewer than 11 claims are excluded from the federal source data, and state comparisons use the average volume among MA prescribers of the same medication. Always confirm current medications and costs directly with the provider and your plan.
